Background: A subgroup of patients with inflammatory bowel disease (IBD) treated with anti–tumor
necrosis factor (TNF) antibodies develop skin lesions, but the lesions and their …

Background and Aims: Mucosal healing is associated with favourable therapeutic outcomes
in patients with ulcerative colitis [UC]. We investigated whether adalimumab concentrations …

The current treatment of Crohn’s disease is limited by a lack of long-term efficacy of
corticosteroid therapy and the associated side effects. Biological treatment strategies aimed at …

Background Antimicrobial peptides (AMPs) protect the host intestinal mucosa against
microorganisms. Abnormal expression of defensins was shown in inflammatory bowel disease (IBD…

Fistulating Crohn's disease (CD) comprises fistulae arising in the perianal area, together with
those communicating between the intestine and other organs or the abdominal wall. The …

When deciding the appropriate treatment strategy for active ulcerative colitis one should
consider the activity, distribution (proctitis, left-sided, extensive 1), and pattern of disease. The …

Background Treatment with infliximab, a chimeric monoclonal IgG1 antibody against tumor
necrosis factor, can result in the formation of antibodies against infliximab. We evaluated the …

Background Fecal calprotectin is a marker of inflammation in inflammatory bowel disease (IBD).
Since mucosal healing has become a goal of treatment in IBD we examined how …

Background Gut-selective blockade of lymphocyte trafficking by vedolizumab may constitute
effective treatment for ulcerative colitis. Methods We conducted two integrated randomized, …

This paper is the first in a series of two publications relating to the European Crohn’s and
Colitis Organisation [ECCO] evidence-based consensus on the diagnosis and management of …